Obinutuzumab for the treatment of lymphoproliferative disorders

Expert Opinion on Biological Therapy

Volumn 12, Issue 3, 2012, Pages 343-351

  Owen, Carolyn ^a   Stewart, Douglas A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antibody; CD20; Chronic lymphocytic leukemia; Lymphoma

Indexed keywords

BENDAMUSTINE; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; OBINUTUZUMAB; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DIRECT CELL DEATH; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HUMAN; IN VITRO STUDY; INDOLENT LYMPHOMA; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD20; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; LYMPHOPROLIFERATIVE DISORDERS;

EID: 84857349967     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.657622     Document Type: Article

References (54)

1. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37 (Pubitemid 47332625)
2. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010;51:983-94
3. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe dEtudes des Lymphomes de lAdulte. Blood 2010;116:2040-5
4. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase III trial. Lancet 2010;376:1164-74
5. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23 (Pubitemid 40223656)
6. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32 (Pubitemid 41742196)
7. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the minnie pearl cancer research network. J Clin Oncol 2003;21:1746-51 (Pubitemid 46638587)
8. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-52 (Pubitemid 36139378)
9. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280-8 (Pubitemid 38263720)
10. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103:2738-43 (Pubitemid 38393032)
11. Racila E, Link BK, Weng WK, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008;14:6697-703
12. Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003;21:1466-71 (Pubitemid 46594097)
13. Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011;10:178-85
14. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type 2, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011;186:3762-9
15. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7 (Pubitemid 36900094)
16. Cittera E, Leidi M, Buracchi C, et al. The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol 2007;178:6616-23 (Pubitemid 46717446)
17. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-69 (Pubitemid 38821999)
18. Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type 1/2 distinction of CD20 antibodies. Blood 2011;118:358-67
19. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkins lymphomas. J Clin Oncol 2001;19:3918-28 (Pubitemid 32912019)
20. Press OW, Unger JM, Braziel RM, et al. A phase II trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: southwest Oncology Group Protocol S9911. Blood 2003;102:1606-12 (Pubitemid 37022549)
21. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011;24:203-16
22. Pedersen AE, Jungersen MB, Pedersen CD. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies. Immunology 2011;133:239-45
23. Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 2008;181:2916-24
24. Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191-201
25. Boyd RS, Jukes-Jones R, Walewska R, et al. Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics 2009;8:1501-15
26. Meyer zum Buschenfelde C, Feuerstacke Y, Gotze KS, et al. GM1 expression of non-Hodgkins lymphoma determines susceptibility to rituximab treatment. Cancer Res 2008;68:5414-22
27. Klepfish A, Gilles L, Ioannis K, et al. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann NY Acad Sci 2009;1173:865-73
28. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8 (Pubitemid 34525533)
29. Koene HR, Kleijer M, Algra J, et al. FcgammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcgammaRIIIa, independently of the FcgammaRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14 (Pubitemid 27314146)
30. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 2008;14:1550-60 (Pubitemid 351413940)
31. Goteri G, Olivieri A, Ranaldi R, et al. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome. Int J Immunopathol Pharmacol 2006;19:421-31 (Pubitemid 44181964)
32. Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113:4885-93
33. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type 2 anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393-402
34. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type 2 anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117:4519-29
35. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-73 (Pubitemid 34832599)
36. Herter S, Waldhauer I, Otz T. Superior efficacy of the novel type 2, glycoengineered CD20 antibody GA101 vs. the type 1 CD20 antiobodies rituximab and ofatumumab. ASH Annual Meeting Abstracts. Blood 2010;116:3925
37. Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119:2143-59
38. Jak M, van Bochove GG, Reits EA, et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type 2 anti-CD20 monoclonal antibody GA101. Blood 2011;118:5178-88
39. Herting F, Bader S, Umana P, Klein C. Enhanced activity of GA101, a novel type 2, glycoengineered CD20 antibody, in combination wtih bendamustine or fludarabine, and with the Bcl-2 family inhibitors ABT-737 or ABT-263. ASH Annual Meeting Abstracts. Blood 2010;116(21):3915a
40. Salles GA, Morschhauser F, Lamy T, et al. Phase I study of R05072759 (GA101) in patients with relapsed/refractory CD20+ non-Hogkin lymphoma (NHL). ASH Annual Meeting Abstracts. Blood 2009;114(22):1704a
41. Morschhauser F, Cartron G, Lamy T, et al. Phase I study of R05072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. Blood 2009;114(22):884a
42. Sehn LH, Assouline SE, Stewart DA, et al. A phase I study of GA101 (R05072759) monotherapy followed by maitenance in patients with multiply relapsed/refractory CD20+ malignant disease. ASH Annual Meeting Abstracts. Blood 2009;114(22):934a
43. Davies A, Radford J, Cartron G, et al. Interim results from a phase IB study of the anti-CD20 antibody obinutuzumab (GA101) in combination with FC or CHOP in relapsed/refractory follicular lymphoma (FL). European Hematology Association Annual Congress. Haematologica 2011;96(s2):0368a
44. Salles GA, Morschhauser F, Thieblemont C, et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL patients -updated results with encouraging progression free survival (PFS) data from a phase II study in patients with relapsed/refractory indolent NHL (iNHL). ASH Annual Meeting Abstracts. Blood 2010;116(21):2868a
45. Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: Preliminary Analysis of the GAUSS study. ASH Annual Meeting Abstracts. Blood 2011;118(22):269a
46. Cartron G, Thieblemont C, Solal-Celigny P, et al. Results from a phase II study (B020999) of R05072759 (GA101) monotherapy in relapsed/refractory aggressive non-Hodgkins lymphoma. International Conference on Malignant Lymphoma. Ann Oncol 2011;22(s4):144a
47. Morschhauser F, Salles G, Cartron G, et al. Dose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101) -a rational approach. European Hematology Association Annual Congress. Haematologica 2011;96(s2):0935a
48. Cartron G, Morshhauser F, Thieblemont C, et al. Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed/refractory chronic lymphocytic leukemia (CLL). European Hematology Association Annual Congress. Haematologica 2011;96(s2):0101a
49. Goede V, Fischer K, Raymonde B, et al. Chemoimmunotherapy with chlorambucil and the type 2 CD20 antibody GA101 in patients with chronic lymphocytic leukemia and comorbidity: results of the run-in phase of the CLL11 (B021004) trial. ASH Annual Meeting Abstracts. Blood 2010;116(21):1387a
50. Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007;62:43-52 (Pubitemid 46330791)
51. Pfreundschuh M, Held G, Zeynalova S, et al. Improved outcome of elderly poor-prognosis DLBCL patients with 6xCHOP-14 and 8 applications of rituximab (R) given over an extended period: results of the SMARTE-RCHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). ASH Annual Meeting Abstracts. Blood 2011;118(22):592a
52. Stolz C, Schuler M. Molecular mechanisms of resistance to rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma 2009;50:873-85
53. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 2009;10:816-24
54. Zayen A, Rais H, Rifi H, et al. Rituximab-induced interstitial lung disease: case report and literature review. Pharmacology 2011;87:318-20